ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment